RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Results from the First Two Years of the FREEDOM Trial Extension
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 5
SP 14
OP 15
DO 10.1177/155989771105010
UL http://mdc.sagepub.com/content/11/5/14.abstract
AB Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months [FREEDOM; NCT00089791] was a randomized, placebo-controlled, Phase 3 trial designed to test the effect of denosumab on risk of fracture in postmenopausal women during a 3-year follow-up period [Cummings SR et al. N Engl J Med 2009].